Progression in cancer trials

[JosieS]

@sme

The second problem is how death would be handled - currently progression is usually a composite of progression or death, which I am certainly not claiming is perfect (or even generally sensible). But I believe the thinking is that death may be a missed progression (which speaks to interval censoring methods again), and, being honest, is a simple way to handle it…

I don’t have much to add to the interesting discussion evolving here, just pointing to an earlier discussion of why we generally use progression-free survival instead of time to progression. It’s not making any assumptions about the cause of death, only that death is also a bad outcome (which can bias assessments of time-to-progression).